We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

WERFEN

Werfen provides diagnostic instruments for critical care and hemostasis to meet the testing needs of medical professi... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Glycoprotein-Specific Direct Platelet Autoantibody Testing in Immune Thrombocytopenia

By LabMedica International staff writers
Posted on 14 Jan 2020
Print article
Image: The NEO Iris is a fully automated immunohematology analyzer for in vitro diagnostic testing of human blood (Photo courtesy of Immucor)
Image: The NEO Iris is a fully automated immunohematology analyzer for in vitro diagnostic testing of human blood (Photo courtesy of Immucor)
Autoantibodies directed against platelet glycoproteins have long been accepted as a major pathophysiologic mechanism in immune thrombocytopenia (ITP), but platelet autoantibody (PA) testing has previously shown poor sensitivity for ITP diagnosis.

Direct assays for platelet autoantibodies, which measure antibodies on platelets, as opposed to indirect assays, which measure free antibodies in plasma, that are capable of detecting glycoprotein-specific autoantibodies are considered optimal for PA testing

Hematologists at the Massachusetts General Hospital (Boston, MA, USA) performed a comprehensive retrospective study of PA testing in adult patients with ITP strictly applying the criteria of the 2012 International Society on Thrombosis and Haemostasis (ISTH) and 2011 American Society of Hematology (ASH) guidelines. Of 986 PA assays performed, 485 assays in 368 patients met criteria and were included.

All PA assays meeting inclusion criteria were performed by using the commercially available PakAuto assay (Immucor, Brookfield, WI, USA), a direct and indirect solid-phase enzyme-linked immunosorbent assay (ELISA)-based test measuring antibodies against GPIIb/IIIa, GPIb/IX, and GPIa/IIa. This direct glycoprotein-specific PA assay measures antibodies eluted from the surface of platelets. A result was positive if optical density values were equal to or greater than two times the value obtained for the mean of the negative controls for the corresponding glycoprotein.

The scientists reported that the sensitivity and specificity of a positive test result for diagnosis of active ITP (n = 228 patients) were 90% and 78%, respectively. Sensitivity and specificity of a negative test result for clinical remission (n = 61 assays) were 87% and 91%. Antibodies against both glycoprotein IIb (GPIIb)/IIIa and GPIb/IX were required for the presence of antibodies against GPIa/IIa in patients with ITP. Logistic regression analysis revealed that more positive autoantibodies predicted more severe disease (relative to nonsevere ITP, relative risk ratio for severe ITP and refractory ITP was 2.27 and 3.09, respectively. Sixty-four patients with ITP had multiple PA assays performed longitudinally: all 10 patients achieving remission converted from positive to negative serologic results, and evidence for epitope spreading was observed in 35% of patients with ongoing active disease.

The authors concluded that glycoprotein-specific direct PA testing performed using ISTH recommendations in patients meeting ASH diagnostic criteria is sensitive and specific for ITP diagnosis and reliably confirms clinical remission. More glycoproteins targeted by autoantibodies predicts for more severe disease. The study was published on December 31, 2019 in the journal Blood Advances.

Related Links:
Massachusetts General Hospital
Immucor


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.